Nutriband Inc. (NASDAQ: NTRB), a company specializing in transdermal pharmaceutical products, has announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit. The event, scheduled for August 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, will bring together leaders from biotechnology, medical technology, research, manufacturing, and investment sectors. Sheridan's presentation will be part of the CEO Spotlight event on August 26.
The summit serves as a platform for discussing innovations and trends in the life sciences industry. Nutriband's participation highlights its ongoing efforts to address the opioid crisis through the development of AVERSA™, an abuse-deterrent transdermal technology. AVERSA™ is designed to incorporate aversive agents into patches, which can help prevent abuse, diversion, misuse, and accidental exposure to drugs with abuse potential, such as fentanyl.
The company's lead product under development is an abuse-deterrent fentanyl patch that utilizes AVERSA™ technology. This technology can be integrated into any transdermal patch to enhance safety and reduce the risk of misuse. By presenting at the summit, Nutriband aims to showcase its innovative approach to a key public health issue, potentially attracting interest from potential partners and investors.
The significance of this presentation lies in the growing concern over opioid abuse and the need for effective solutions. Nutriband's AVERSA™ technology could play a crucial role in mitigating the risks associated with prescription opioids, which have been a major contributor to addiction and overdose deaths. By participating in the summit, Nutriband positions itself at the forefront of abuse-deterrent technology, potentially influencing industry standards and regulatory practices.
Moreover, the summit provides an opportunity for Nutriband to network with key stakeholders, including researchers, manufacturers, and investors, which could facilitate collaborations and funding for further development. The company's commitment to addressing this critical issue is underscored by its active involvement in industry events and its focus on bringing AVERSA™ to market.
For more information about Nutriband and its products, visit the company's website at www.nutriband.com. The latest news and updates regarding NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
The full press release can be accessed at https://ibn.fm/Un3ax.
